Literature DB >> 9440703

Antithrombotic effects of recombinant human, active site-blocked factor VIIa in a rabbit model of recurrent arterial thrombosis.

P Golino1, M Ragni, P Cirillo, D D'Andrea, A Scognamiglio, A Ravera, C Buono, M Ezban, N Corcione, F Vigorito, M Condorelli, M Chiariello.   

Abstract

The extrinsic coagulation pathway is activated when circulating factor VII (FVII) gains access to tissue factor (TF) exposed as a consequence of vascular injury. Increasing evidence indicates that this TF-dependent activation of the coagulation plays an important role in the pathophysiology of intravascular thrombus formation. In the present study, we tested the effects of recombinant human, active site-blocked activated FVII (FVIIai) in a rabbit model of carotid artery thrombosis. Cyclic flow variations (CFVs), due to recurrent thrombus formation, were obtained in stenotic rabbit carotid arteries with endothelial injury. Carotid blood flow velocity was measured by a Doppler flow probe. After 30 minutes of CFVs, the animals received FVIIai (100 microg x kg(-1) x min(-1) intracarotid infusion for 10 minutes, n=9). If CFVs were abolished, animals were followed for 30 additional minutes, after which recombinant human activated FVII (FVIIa) was infused into the carotid artery (100 microg x kg(-1) x min(-1) for 10 minutes) to determine whether FVIIai could be displaced from TF by FVIIa, thus restoring CFVs. To establish the duration of action of FVIIai, an additional group of animals received FVIIai at the same dose as above, and after CFVs were inhibited, they were followed until CFVs were restored or for up to 6 hours. To determine whether CFVs could be restored by epinephrine after their abolition with FVIIai, increasing doses of epinephrine were administered to a third group of 6 animals. FVIIai abolished CFVs in 8 of 9 rabbits (P<.01). This effect was reversible, as FVIIa administration restored CFVs in all animals. Prothrombin times and activated partial thromboplastin times did not change significantly throughout the study. One single 10-minute infusion exerted complete antithrombotic effects for at least 6 hours, despite the fact that at this time point, plasma FVIIai levels were well below threshold concentrations. Epinephrine restored CFVs in 3 of 6 animals in which CFVs were inhibited by FVIIai. FVIIai exerts potent antithrombotic effects in this model; these effects were prolonged even after FVIIai was almost completely cleared from the circulation, probably as a result of the tight binding of FVIIai to TF. Thus, FVIIai might represent an antithrombotic substance of potential interest.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9440703     DOI: 10.1161/01.res.82.1.39

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  10 in total

Review 1.  New anticoagulants: beyond heparin, low-molecular-weight heparin and warfarin.

Authors:  Shannon M Bates; Jeffrey I Weitz
Journal:  Br J Pharmacol       Date:  2005-04       Impact factor: 8.739

Review 2.  Tissue factor: newer concepts in thrombosis and its role beyond thrombosis and hemostasis.

Authors:  Giovanni Cimmino; Plinio Cirillo
Journal:  Cardiovasc Diagn Ther       Date:  2018-10

3.  Factor VIIa interaction with EPCR modulates the hemostatic effect of rFVIIa in hemophilia therapy: Mode of its action.

Authors:  Shiva Keshava; Jagan Sundaram; Anuradha Rajulapati; Charles Esmon; Usha Pendurthi; L Vijaya Mohan Rao
Journal:  Blood Adv       Date:  2017-06-27

4.  Reactive oxygen species induce a procoagulant state in endothelial cells by inhibiting tissue factor pathway inhibitor.

Authors:  Giovanni Cimmino; Plinio Cirillo; Massimo Ragni; Stefano Conte; Giuseppe Uccello; Paolo Golino
Journal:  J Thromb Thrombolysis       Date:  2015-08       Impact factor: 2.300

Review 5.  Inhibitors of the initiation of coagulation.

Authors:  Ilka Ott
Journal:  Br J Clin Pharmacol       Date:  2011-10       Impact factor: 4.335

Review 6.  Pharmacologic reperfusion therapy for acute myocardial infarction.

Authors:  Harry C Lowe; Briain D Mac Neill; Frans Van de Werf; Ik-Kyung Jang
Journal:  J Thromb Thrombolysis       Date:  2002-12       Impact factor: 2.300

Review 7.  Advancement in antithrombotics for stroke prevention in atrial fibrillation.

Authors:  Mohammed Haris Umer Usman; Sabreen Raza; Shariq Raza; Michael Ezekowitz
Journal:  J Interv Card Electrophysiol       Date:  2008-04-17       Impact factor: 1.900

8.  Vascular smooth muscle-derived tissue factor is critical for arterial thrombosis after ferric chloride-induced injury.

Authors:  Li Wang; Christine Miller; Robert F Swarthout; Mohan Rao; Nigel Mackman; Mark B Taubman
Journal:  Blood       Date:  2008-10-17       Impact factor: 22.113

Review 9.  Antiphospholipid antibody effects on monocytes.

Authors:  Alisa S Wolberg
Journal:  Curr Rheumatol Rep       Date:  2007-06       Impact factor: 4.686

10.  Tissue Factor/Factor FVII Complex Inhibitors in Cardiovascular Disease. Are Things Going Well?

Authors:  Gianluca Petrillo; Plinio Cirillo; Greta-Luana D'Ascoli; Fabio Maresca; Francesca Ziviello; Massimo Chiariello
Journal:  Curr Cardiol Rev       Date:  2010-11
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.